JAMA (Journal of the American Medical Association)
Открыть в Telegram
All the latest articles published on JAMA before going in to print Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot
Больше📈 Аналитический обзор Telegram-канала JAMA (Journal of the American Medical Association)
Канал JAMA (Journal of the American Medical Association) (@jamaupdates) языкового сегмента Английский является активным участником. Сейчас сообщество объединяет 16 562 подписчиков, занимая 1 466 место в категории Медицина и 2 239 место в регионе США.
📊 Показатели аудитории и динамика
С момента создания невідомо проект демонстрирует стремительный рост, собрав аудиторию из 16 562 подписчиков.
Согласно последним данным от 06 октября, 2026, канал показывает стабильную активность. За последние 30 дней изменение числа участников составило 288, а за последние 24 часа — 17, при этом общий охват остаётся высоким.
- Статус верификации: Не верифицирован
- Уровень вовлечённости (ER): Средний показатель вовлечённости аудитории составляет 4.02%. В первые 24 часа после публикации контент обычно набирает 1.91% реакций от общего числа подписчиков.
- Охват публикаций: В среднем каждый пост получает 666 просмотров. В течение первых суток публикация набирает 316 просмотров.
- Реакции и взаимодействия: Аудитория активно поддерживает контент: среднее количество реакций на один пост — 1.
- Тематические интересы: Контент сосредоточен на ключевых темах, таких как patient, disease, treatment, drug, guideline.
📝 Описание и контентная политика
Автор описывает ресурс как площадку для выражения субъективного мнения:
“All the latest articles published on JAMA before going in to print
Discussion Group
https://t.me/Medical_Professionals_Forum
Contact us
https://t.me/Contact_Updates_in_Medicine_Bot”
Благодаря высокой частоте обновлений (последние данные получены 07 октября, 2026) канал поддерживает актуальность и высокий уровень охвата публикаций. Аналитика показывает, что аудитория активно взаимодействует с контентом, что делает его важной точкой влияния в категории Медицина.
16 562
Подписчики
+1724 часа
+667 дней
+28830 дней
Загрузка данных...
Похожие каналы
Облако тегов
Входящие и исходящие упоминания
---
---
---
---
---
---
Привлечение подписчиков
октябрь '26окт. '26
октябрь '26
+54
в 0 каналах
сентябрь '26
+301
в 0 каналах
Get PRO
август '26
+361
в 0 каналах
Get PRO
июль '26
+440
в 0 каналах
Get PRO
июнь '26
+422
в 0 каналах
Get PRO
май '26
+584
в 0 каналах
Get PRO
апрель '26
+437
в 0 каналах
Get PRO
март '26
+217
в 0 каналах
Get PRO
февраль '26
+247
в 0 каналах
Get PRO
январь '26
+321
в 0 каналах
Get PRO
декабрь '25
+277
в 0 каналах
Get PRO
ноябрь '25
+366
в 2 каналах
Get PRO
октябрь '25
+164
в 0 каналах
Get PRO
сентябрь '25
+12
в 0 каналах
Get PRO
август '25
+29
в 0 каналах
Get PRO
июль '25
+30
в 0 каналах
Get PRO
июнь '25
+17
в 0 каналах
Get PRO
май '25
+9
в 0 каналах
Get PRO
апрель '25
+5
в 0 каналах
Get PRO
март '25
+17
в 0 каналах
Get PRO
февраль '25
+12
в 0 каналах
Get PRO
январь '25
+18
в 1 каналах
Get PRO
декабрь '24
+237
в 0 каналах
Get PRO
ноябрь '24
+1 122
в 0 каналах
Get PRO
октябрь '24
+1 120
в 0 каналах
Get PRO
сентябрь '24
+1 527
в 1 каналах
Get PRO
август '24
+1 128
в 1 каналах
Get PRO
июль '24
+1 216
в 0 каналах
Get PRO
июнь '24
+781
в 1 каналах
Get PRO
май '24
+797
в 1 каналах
Get PRO
апрель '24
+808
в 1 каналах
Get PRO
март '24
+821
в 2 каналах
Get PRO
февраль '24
+753
в 1 каналах
Get PRO
январь '24
+768
в 0 каналах
Get PRO
декабрь '23
+716
в 1 каналах
Get PRO
ноябрь '23
+96
в 1 каналах
Get PRO
октябрь '23
+86
в 0 каналах
Get PRO
сентябрь '23
+73
в 0 каналах
Get PRO
август '23
+90
в 0 каналах
Get PRO
июль '23
+107
в 0 каналах
Get PRO
июнь '23
+105
в 0 каналах
Get PRO
май '23
+169
в 0 каналах
Get PRO
апрель '23
+128
в 0 каналах
Get PRO
март '23
+84
в 0 каналах
Get PRO
февраль '23
+75
в 0 каналах
Get PRO
январь '23
+71
в 0 каналах
Get PRO
декабрь '22
+74
в 0 каналах
Get PRO
ноябрь '22
+149
в 0 каналах
Get PRO
октябрь '22
+90
в 0 каналах
Get PRO
сентябрь '22
+138
в 0 каналах
Get PRO
август '22
+77
в 0 каналах
Get PRO
июль '22
+50
в 0 каналах
Get PRO
июнь '22
+96
в 0 каналах
Get PRO
май '22
+75
в 0 каналах
Get PRO
апрель '22
+80
в 0 каналах
Get PRO
март '22
+65
в 0 каналах
Get PRO
февраль '22
+26
в 0 каналах
Get PRO
январь '22
+56
в 0 каналах
Get PRO
декабрь '21
+44
в 0 каналах
Get PRO
ноябрь '21
+39
в 0 каналах
Get PRO
октябрь '21
+61
в 0 каналах
Get PRO
сентябрь '21
+66
в 0 каналах
Get PRO
август '21
+65
в 0 каналах
Get PRO
июль '21
+96
в 0 каналах
Get PRO
июнь '21
+120
в 0 каналах
Get PRO
май '21
+130
в 0 каналах
Get PRO
апрель '21
+812
в 0 каналах
| Дата | Привлечение подписчиков | Упоминания | Каналы | |
| 07 октября | +4 | |||
| 06 октября | +17 | |||
| 05 октября | +7 | |||
| 04 октября | +11 | |||
| 03 октября | +5 | |||
| 02 октября | +8 | |||
| 01 октября | +2 |
Посты канала
Hypertension Management and Control in Cienfuegos, Cuba
https://jamanetwork.com/journals/jama/fullarticle/2854963
This population-based cross-sectional survey assesses hypertension prevalence and indicators of management and control in 2023 and compares these findings with a similar population-based survey conducted in 2011.
| 2 | Facilitating Real-World Advance Care Planning
https://jamanetwork.com/journals/jama/fullarticle/2854964
Advance care planning (ACP) and serious illness communication guides complex medical care and is widely recommended in national guidelines, quality metrics, and Medicare policy, which has allowed physician reimbursement for ACP conversations since 2016. Yet prior research reveals disparities in serious illness care among Black individuals in the United States, and there is a paucity of research on the effectiveness of ACP interventions among them. Possible reasons for these disparities include, but are not limited to, inequitable access to health care and justifiable distrust in the health system. | 78 |
| 3 | Beyond the Trial—What Do Extension Studies Add to Randomized Clinical Trials?
https://jamanetwork.com/journals/jama/fullarticle/2854965
One critical shortcoming of many clinical therapeutic trials is their focus on short-term effects, leaving unanswered questions about how participants fare in the longer term. Trial extension studies are conducted to address this gap, allowing assessment of both durability of treatment benefit (eg, whether disease remission or improvements in function are maintained or diminished over time) and long-term safety (such as incidence of delayed adverse events). In therapeutic trials, extension studies can mitigate the ethical burden associated with discontinuation of potentially effective treatments or long-term administration of placebo or inferior interventions among those initially assigned to the control group. The prospect of an extension study may also give participants greater incentive to enroll in trials, despite concerns about being assigned to the control group in the initial phase of the research. Because extension studies build on existing trial infrastructure, they also allow additional and potentially valuable information to be derived from trials that already require significant up-front investment. | 71 |
| 4 | Multiple Violaceous-to-Brownish Patches and Plaques on the Trunk
https://jamanetwork.com/journals/jama/fullarticle/2854966
A patient with a history of lung adenocarcinoma had violaceous-to-brown cutaneous patches and plaques. Computed tomography showed splenomegaly and multicentric lymphadenopathy, and laboratory testing showed an elevated erythrocyte sedimentation rate and levels of IgG, IgG4, IgA, and interleukin 6. What is the diagnosis and what would you do next? | 55 |
| 5 | The Quiet Half of Good Medicine
https://jamanetwork.com/journals/jama/fullarticle/2854957
This Viewpoint discusses the need to discern when medical intervention is needed vs when supportive care and monitoring are appropriate. | 67 |
| 6 | Hypertension Control in Low- and Middle-Income Settings
https://jamanetwork.com/journals/jama/fullarticle/2855205
Hypertension control is among the most urgent and attainable priorities in global cardiovascular health. High blood pressure remains a leading cause of myocardial infarction, stroke, heart failure, chronic kidney disease, and dementia, yet it can be detected with a simple measurement and treated with effective, inexpensive medicines. The World Health Organization (WHO) estimates that 1.4 billion adults aged 30 to 79 years had hypertension in 2024 and that only 320 million, or 23%, had their blood pressure controlled. Ninety-nine countries had national control rates below 20%. The gap is widest in low- and middle-income countries (LMICs), where most people with hypertension live and health systems must address a large cardiovascular disease burden with limited resources. | 74 |
| 7 | Landmark Significance and Future Directions of the RAPID-TEST Trial
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2854545
To the Editor The RAPID-TEST trial by Hay et al represents to our knowledge the first pragmatic randomized clinical trial to evaluate the use of multiplex molecular point-of-care testing (POCT) for respiratory tract infections in primary care. It establishes a rigorous evidence benchmark for the field. At the same time, its design limitations and evidence gaps provide a critical roadmap for future advancement. | 478 |
| 8 | Expiration of Pandemic Food Assistance and Food Insufficiency in Adults With Disabilities
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2854546
This cross-sectional study explores the prevalence of food insufficiency following the end of SNAP emergency allotments among adults with disabilities in 22 US states. | 458 |
| 9 | From Positive FIT Result to Colonoscopy—Closing a Gap in Care
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2854548
Colorectal cancer screening is effective, yet underused. Fortunately, patients have a variety of options. They can select screening colonoscopy as the initial step, which offers the greatest sensitivity for advanced neoplasia, or take a 2-step approach that begins with a stool test. An advantage of the stool tests, such as the fecal immunochemical test (FIT), is that 9 out of 10 patients will have a negative test result and will not require a follow-up colonoscopy. | 426 |
| 10 | Low-Dose Rivaroxaban, Cardiovascular Events, and Kidney Disease—Reply
https://jamanetwork.com/journals/jama/fullarticle/2854849
In Reply TRACK was designed against a background of evidence that rivaroxaban at a dose far lower than required for therapeutic anticoagulation may provide cardiovascular protection with a favorable benefit-risk profile in advanced kidney disease. We agree with Dr Coppi that the results of our trial demonstrated that much of the cardiovascular disease in advanced kidney disease may not be atherothrombotic in nature and therefore may not be modifiable by atherothrombotic treatments. However, we do not concur with other assertions made by Dr Coppi. Patients with advanced kidney disease have been systematically excluded from cardiovascular outcome trials of antiplatelet agents. Observational studies have reported increased mortality with aspirin and clopidogrel use in patients receiving hemodialysis. Until dedicated cardiovascular outcome trials of antiplatelet agents in advanced kidney disease are completed and reported (eg, the Aspirin in Reducing Events in Dialysis [ASPIRED] trial), it is premature to assume that these therapies are safe or beneficial for broad cardiovascular risk reduction in this population. | 352 |
| 11 | Medicare and Bureau of Health Workforce and Funded Primary Care Residency Positions
https://jamanetwork.com/journals/jama/fullarticle/2854850
To the Editor We are writing about the Research Letter “Changes in Specialty and Geography of Medicare’s New Residency Positions,” which reported that Medicare-funded expansion has not substantially increased primary care or rural training capacity. However, we would like to highlight an important limitation of specialty-based workforce estimates: residency positions labeled as primary care may not accurately reflect the production of physicians who enter primary care practice. Because these estimates rely on specialty designation, they may overstate primary care workforce contributions and fail to capture graduates’ postresidency practice. | 266 |
| 12 | Low-Dose Rivaroxaban, Cardiovascular Events, and Kidney Disease
https://jamanetwork.com/journals/jama/fullarticle/2854851
To the Editor I read with great interest the Treatment of Cardiovascular Disease With Low-Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK) trial and the insightful accompanying editorial regarding the use of low-dose rivaroxaban in patients with advanced chronic kidney disease (CKD). Although the investigators should be commended for undertaking this trial in a historically excluded population, the lack of cardiovascular efficacy and significant increase in major bleeding events highlight critical methodological limitations that warrant a strategic paradigm shift in future trial designs involving direct oral anticoagulants (DOACs) in end-stage kidney disease. | 251 |
| 13 | Opportunities and Challenges in Tobacco Treatment
https://jamanetwork.com/journals/jama/fullarticle/2854853
Evidence-based treatments and comprehensive tobacco control policies have driven a marked decline in cigarette smoking among US adults over time. Approximately 25 million adults in the US continue to smoke, a prevalence of 9.9%. The declines in cigarette smoking have not been evenly distributed, with higher smoking rates, reduced access to cessation support, and higher tobacco-related mortality among individuals with lower socioeconomic status, certain racial and ethnic minority populations, and those with mental health and/or substance use disorders. | 248 |
| 14 | Ten Years of Ocrelizumab in Relapsing Multiple Sclerosis
https://jamanetwork.com/journals/jamaneurology/fullarticle/2854792
The open-label extension of the OPERA I and II randomized clinical trials assesses 10-year safety and efficacy of ocrelizumab in patients with relapsing multiple sclerosis. | 290 |
| 15 | Blood-Based Biomarkers, Diagnostic Certainty, and Clinical Management
https://jamanetwork.com/journals/jamaneurology/fullarticle/2854793
This randomized clinical trial evaluates whether earlier disclosure of plasma phosphorylated tau at threonine 217 and neurofilament light chain affects diagnostic certainty and clinical management. | 296 |
| 16 | Rapid Whole-Genome Sequencing in Pediatric Neurology Inpatients
https://jamanetwork.com/journals/jamaneurology/fullarticle/2854794
This cohort study investigates the diagnostic yield and clinical impact of rapid whole-genome sequencing in pediatric neurology inpatients, and which clinical features are associated with a phenotype-concordant diagnosis. | 323 |
| 17 | Precision Care for Children With Neurologic Disease
https://jamanetwork.com/journals/jamaneurology/fullarticle/2854795
Diagnostic uncertainty hinders appropriate management, counseling, and holistic family care in children with pediatric neurological diseases. Whole-genome sequencing is now providing a new light in a dark tunnel for these children and their families. This is of greater relevance as genetic precision therapies, such as N-of-1 gene therapy programs, continue to emerge with efficacy greatest before irreversible neuronal injury. | 355 |
| 18 | Error in Figure
https://jamanetwork.com/journals/jamaneurology/fullarticle/2854796
The Research Letter titled “Temporal Patterns in Stroke Recurrence at Younger Ages: A Systematic Review and Meta-Analysis,” published online April 27, 2026, and in the June issue, had decimal errors in a portion of the y-axis labels in all 3 panels in the Figure. This article was corrected online. | 354 |
| 19 | Autism Incidence Has Remained Stable, Study Finds
https://jamanetwork.com/journals/jama/fullarticle/2854953
The incidence of autism spectrum disorder in South Korea remained stable across cohorts born from 1998 to 2010, according to a study published in JAMA Pediatrics. | 752 |
| 20 | Semaglutide Demonstrates Benefits Across Frailty Levels
https://jamanetwork.com/journals/jama/fullarticle/2854954
The glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide demonstrated safety and efficacy regardless of frailty status, a study published in JAMA Cardiology found. | 709 |
